• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Echocardiographic Risk Factors for Stroke and Outcomes in Patients With Atrial Fibrillation Anticoagulated With Apixaban or Warfarin Clinical Sciences
Conclusions—In anticoagulated patients with atrial fibrillation and risk factors for stroke, echocardiographic findings do not seem to add to the risk of thromboembolic events.Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00412984.
Source: Stroke - November 27, 2017 Category: Neurology Authors: Dragos Vinereanu, Renato D. Lopes, Hillary Mulder, Bernard J. Gersh, Michael Hanna, Pedro G.M. de Barros e Silva, Dan Atar, Lars Wallentin, Christopher B. Granger, John H. Alexander Tags: Arrhythmias, Echocardiography, Intracranial Hemorrhage, Ischemic Stroke Original Contributions Source Type: research

Warfarin Use in Patients With Atrial Fibrillation Undergoing Hemodialysis Clinical Sciences
Conclusions—Our findings suggest that warfarin should be used carefully in hemodialysis patients, given the higher risk of hemorrhagic events and the lack of ability to prevent thromboembolic complications.
Source: Stroke - August 28, 2017 Category: Neurology Authors: Chang-Yun Yoon, Juhwan Noh, Jong Hyun Jhee, Tae Ik Chang, Ea Wha Kang, Youn Kyung Kee, Hyoungnae Kim, Seohyun Park, Hae-Ryong Yun, Su-Young Jung, Hyung Jung Oh, Jung Tak Park, Seung Hyeok Han, Shin-Wook Kang, Changsoo Kim, Tae-Hyun Yoo Tags: Arrhythmias, Clinical Studies, Nephrology and Kidney, Intracranial Hemorrhage, Ischemic Stroke Original Contributions Source Type: research

Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack Clinical Sciences
Conclusions—Results from our study of the 3 NOACs versus warfarin in nonvalvular atrial fibrillation patients with a previous history of stroke/transient ischemic attack are relatively consistent with their respective phase III trials and previous stroke/transient ischemic attack subgroup analyses. All NOACs seemed no worse than warfarin in respect to ischemic stroke, ICH, or major bleeding risk.
Source: Stroke - July 24, 2017 Category: Neurology Authors: Craig I. Coleman, W. Frank Peacock, Thomas J. Bunz, Mark J. Alberts Tags: Arrhythmias, Quality and Outcomes, Intracranial Hemorrhage, Ischemic Stroke Original Contributions Source Type: research

Geographic Variation in the Use of Oral Anticoagulation Therapy in Stroke Prevention in Atrial Fibrillation Brief Report
Conclusions—Large geographic variation exists in oral anticoagulation use in atrial fibrillation. The use of oral anticoagulation is lower in the South, where the rates of stroke are unusually high. In the future, it will be important to analyze whether the high rates of stroke in the South can be partially attributed to the underuse of oral anticoagulation in this region.
Source: Stroke - July 24, 2017 Category: Neurology Authors: Inmaculada Hernandez, Samir Saba, Yuting Zhang Tags: Arrhythmias, Anticoagulants, Health Services, Ischemic Stroke Brief Reports Source Type: research

Statin Adherence Is Associated With Reduced Recurrent Stroke Risk in Patients With or Without Atrial Fibrillation Clinical Sciences
Conclusions—The relationship between statin adherence and reduced recurrent stroke risk is as strong among patients with AFib as it is among patients without AFib, suggesting that AFib status should not be a reason to exclude patients from secondary stroke prevention with a statin.
Source: Stroke - June 26, 2017 Category: Neurology Authors: Alexander C. Flint, Carol Conell, Xiushui Ren, Hooman Kamel, Sheila L. Chan, Vivek A. Rao, S. Claiborne Johnston Tags: Arrhythmias, Lipids and Cholesterol, Secondary Prevention, Ischemic Stroke Original Contributions Source Type: research

Response by Bai et al to Letter Regarding Article, “Rivaroxaban Versus Dabigatran or Warfarin in Real-World Studies of Stroke Prevention in Atrial Fibrillation: Systematic Review and Meta-Analysis” Letter to the Editor
Source: Stroke - May 22, 2017 Category: Neurology Authors: Ying Bai, Alena Shantsila, Gregory Y.H. Lip Tags: Arrhythmias Letters to the Editor Source Type: research

Letter by Chen et al Regarding Article, “Left Ventricular Eȷection Fraction and Risk of Stroke and Cardiac Events in Heart Failure: Data From the Warfarin Versus Aspirin in Reduced Eȷection Fraction Trial” Letter to the Editor
Source: Stroke - November 27, 2016 Category: Neurology Authors: Chen Chen, Dongze Li, Lixia Deng Tags: Arrhythmias, Heart Failure, Complications, Cerebrovascular Disease/Stroke Letters to the Editor Source Type: research

Antithrombotic Therapy After Acute Ischemic Stroke in Patients With Atrial Fibrillation Clinical Sciences
Conclusions— Contrary to current guidelines, 30% of patients with atrial fibrillation and recent IS are not prescribed any OAC therapy on discharge, whereas a further 30% are prescribed combination OAC and antiplatelet therapy. Combination OAC and antiplatelet therapy in patients at high cardiovascular risk requires evaluation in clinical trials, particularly with the newer OACs, given their more favorable risk–benefit ratio compared with warfarin.
Source: Stroke - November 24, 2014 Category: Neurology Authors: McGrath, E. R., Kapral, M. K., Fang, J., Eikelboom, J. W., Conghaile, A. O., Canavan, M., O'Donnell, M. J., on behalf of the Investigators of the Ontario Stroke Registry Tags: Secondary prevention, Acute Cerebral Infarction, Arrhythmias, clinical electrophysiology, drugs Clinical Sciences Source Type: research

High Prevalence of Atrial Fibrillation Among Patients With Ischemic Stroke Clinical Sciences
Conclusions— Access to nationwide register data shows that AF is more common among patients with ischemic stroke than those previously reported. Few patients with stroke and AF had anticoagulant treatment before the event, and few got it after the event. CHA2DS2-VASc could be a useful monitoring tool to intensify efforts to diagnose AF among patients with cryptogenic stroke.
Source: Stroke - August 25, 2014 Category: Neurology Authors: Friberg, L., Rosenqvist, M., Lindgren, A., Terent, A., Norrving, B., Asplund, K. Tags: Coumarins, Arrhythmias, clinical electrophysiology, drugs, Embolic stroke, Epidemiology Clinical Sciences Source Type: research

Intracranial Hemorrhage Mortality in Atrial Fibrillation Patients Treated With Dabigatran or Warfarin Clinical Sciences
Conclusions— In this sample of AF patients with ICB on oral anticoagulants, dabigatran was not associated with higher in-hospital mortality compared with warfarin. Hence, reluctance to use dabigatran because of a lack of approved reversal agents is not supported by our results.
Source: Stroke - July 28, 2014 Category: Neurology Authors: Alonso, A., Bengtson, L. G. S., MacLehose, R. F., Lutsey, P. L., Chen, L. Y., Lakshminarayan, K. Tags: Cerebrovascular disease/stroke, Coumarins, Other anticoagulants, Arrhythmias, clinical electrophysiology, drugs, Anticoagulants Clinical Sciences Source Type: research

Cerebrovascular Events in 21 105 Patients With Atrial Fibrillation Randomized to Edoxaban Versus Warfarin: Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 Clinical Sciences
Conclusions— In patients with atrial fibrillation, once-daily edoxaban was as effective as warfarin in preventing all strokes, with significant reductions in various subtypes of intracranial bleeding. Ischemic cerebrovascular event rates were similar with high-dose edoxaban and warfarin, whereas low-dose edoxaban was less effective than warfarin. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00781391.
Source: Stroke - July 28, 2014 Category: Neurology Authors: Giugliano, R. P., Ruff, C. T., Rost, N. S., Silverman, S., Wiviott, S. D., Lowe, C., Deenadayalu, N., Murphy, S. A., Grip, L. T., Betcher, J. M., Duggal, A., Dave, J., Shi, M., Mercuri, M., Antman, E. M., Braunwald, E., on behalf of the ENGAGE AF-TIMI 48 Tags: Other anticoagulants, Acute Cerebral Hemorrhage, Acute Cerebral Infarction, Arrhythmias, clinical electrophysiology, drugs Clinical Sciences Source Type: research

Warfarin Versus Aspirin for Prevention of Cognitive Decline in Atrial Fibrillation: Randomized Controlled Trial (Birmingham Atrial Fibrillation Treatment of the Aged Study) Clinical Sciences
Conclusions— We found no evidence that anticoagulation confers clinically important protection over aspirin against cognitive decline as measured by the Mini-Mental State Examination in atrial fibrillation in the first 33 months of treatment other than that provided by preventing clinical stroke. Clinical Trial Registration— URL: http://www.controlled-trials.com. Unique identifier: ISRCTN89345269.
Source: Stroke - April 28, 2014 Category: Neurology Authors: Mavaddat, N., Roalfe, A., Fletcher, K., Lip, G. Y. H., Hobbs, F. D. R., Fitzmaurice, D., Mant, J. Tags: Arrhythmias, clinical electrophysiology, drugs, Primary and Secondary Stroke Prevention, Anticoagulants Clinical Sciences Source Type: research

Atrial Fibrillation, Stroke Risk, and Warfarin Therapy Revisited: A Population-Based Study Clinical Sciences
Conclusions— AF is more common than present guidelines suggest. The attributable risk of AF for ischemic stroke increases with age and is close to that of hypertension in individuals aged ≥80 years. Because a majority of patients with AF with increased risk for stroke had not received anticoagulation therapy, there is a large potential for improvement.
Source: Stroke - October 21, 2013 Category: Neurology Authors: Bjorck, S., Palaszewski, B., Friberg, L., Bergfeldt, L. Tags: Cerebrovascular disease/stroke, Acute Cerebral Hemorrhage, Acute Cerebral Infarction, Arrhythmias, clinical electrophysiology, drugs, Epidemiology Clinical Sciences Source Type: research